

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number
WO 03/035623 A1

- (51) International Patent Classification⁷: **C07D 211/90**
- (21) International Application Number: **PCT/US02/33894**
- (22) International Filing Date: 23 October 2002 (23.10.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/346,250 24 October 2001 (24.10.2001) US
- (71) Applicant (for all designated States except US): **SEPRACOR, INC.** [US/US]; 84 Waterford Drive, Marlborough, MA 01752-7010 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **SENANAYAKE, Chris, H.** [US/US]; 11 Old Farm Circle, Shrewsbury, MA 01545 (US). **TANOURY, Gerald, J.** [US/US]; 1 Orchard Drive, Hudson, MA 01749 (US). **WILKINSON, Harold, S.** [CA/US]; 313 Diconzo Blvd., Marlborough, MA 01752 (US). **BAKALE, Roger, P.** [US/US]; 4 Cornstock Drive, Shrewsbury, MA 01545 (US). **ZLOTA, Andrei, A.** [US/US]; 15 Fairbanks Road, Sharon, MA 02067 (US).
- (74) Agents: **HALSTEAD, David, P.** et al.; Ropes & Gray, One International Place, Boston, MA 02110-2624 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/035623 A1

(54) Title: METHOD OF RESOLVING AMLODIPINE RACEMATE

(57) Abstract: The invention relates to methods of resolving racemic amlodipine into enantiomerically enriched compositions by precipitation with tartaric acid in the presence of a non-aqueous solvent, such as N,N'-dimethylacetamide. The molar ratio of tartaric acid:amlodipine is preferably less than 0.25:1.0 greater than 0.75:1.0.

METHOD OF RESOLVING AMLODIPINE RACEMATE

Field of the Invention

Amlodipine is a long-acting, dihydropyridine-type inhibitor of the slow calcium channel that is useful in the treatment of hypertension and coronary insufficiency. Amlodipine contains a single asymmetric carbon. The calcium channel blocking activity resides primarily in the *S*-(-) amlodipine enantiomer. The present invention is directed to a method of resolving racemic amlodipine into its *R*-(+) and *S*-(-) enantiomers by precipitation with tartaric acid.

Background of the Invention

The synthesis of racemic amlodipine (3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate) and its activity as an inhibitor of calcium channels is described in U.S. patent No. 4,572,909 to Campbell et al. Results of *in vitro* tests to determine calcium antagonist activity of amlodipine enantiomers against calcium-induced constriction of potassium-depolarized rat aorta is described in Arrowsmith et al., *J. Med. Chem.*, (1986) 29, 1696-1702. The authors allege that the (-) stereoisomer is twice as active as the racemic mixture in antagonizing calcium-induced constriction. The *S* absolute configuration is the (-) optical rotatory form. Goldmann, *J. Med. Chem.*, (1992) 35, 3341-44. Desirability of optically pure *S*-(-)-amlodipine for treatment of hypertension and angina is described in U.S. patent No. 6,057,344.

Although *R*-(+)-amlodipine appears to have little activity as a calcium channel blocker, it is not pharmacologically inert, but rather it is a potent inhibitor of smooth muscle cell migration. WO 95/05822 (now U.S. Patent No. 6,080,761) to Chahwala et al. Ideally, the preferred mode of using amlodipine would be the administration of the *S*-(-) enantiomer substantially free of the *R*-(+) enantiomer. U.S. Patent No. 6,057,344 to Young. Nonetheless, there is presently no amlodipine

product that contains *S*-(-)-amlodipine substantially free of the *R*-(+) enantiomer. See, for example, NORVASC®, the active ingredient of which is racemic amlodipine besylate.

Methods of producing enantiomerically pure amlodipine have concentrated on methods of resolving the racemate, *i.e.*, methods of separating the enantiomers of a racemic mixture of amlodipine or an intermediate in the synthesis of amlodipine by stereoselective precipitation. Such methods are known. See EP 331 315 A2 to Arrowsmith (resolution of an amlodipine intermediate by cinchonidine).

Spargo described a method of resolving racemic amlodipine by forming a precipitate in a dimethylsulfoxide (DMSO) solvent by addition of D- or L-tartaric acid. WO 95/25722 (now U.S. Patent No. 6,046,338). The resultant precipitate consists of amlodipine:tartrate:DMSO in a 2:1:2 ratio, which is termed an amlodipine hemitartrate DMSO monosolvate.

Spargo optionally allowed for the presence of a co-solvent in an amount that is preferably between 0.2% and 6 % the volume of DMSO. Suitable co-solvents are taught to include dimethylacetamide, dimethylformamide (DMF), acetonitrile and tetrahydrofuran (THF). Spargo further describes a method of secondarily processing the amlodipine hemitartrate DMSO monosolvate to obtain crystalline amlodipine free base by a process of extraction of the amlodipine hemitartrate DMSO monosolvate in dichloromethane (DCM) with aqueous NaOH to remove the tartrate followed by precipitation with hexane.

However, the use of DMSO renders the method of Spargo unsuitable for large-scale (kilogram) routine production of enantiomeric amlodipine. FDA guidelines point out that DMSO residual concentrations above 0.5% would only be acceptable upon convincing justification. *Guidance for Industry IMPURITIES: RESIDUAL SOLVENTS*, FDA, Sept. 1999, page 9. Accordingly, there is an art-recognized need for commercially acceptable large-scale methods of resolving amlodipine.

Summary of the Invention

In one aspect, the invention is directed to a method of optically enriching racemic amlodipine, comprising precipitating amlodipine hemitartrate dimethylacetamide monosolvate from a solution comprising amlodipine and either D- or L-tartaric acid, whereby the amlodipine hemitartrate dimethylacetamide monosolvate precipitate is enriched for one enantiomer of amlodipine. In certain embodiments, the ratio of the two enantiomers of amlodipine in the precipitate is at least 8:1, preferably at least 9:1, or even at least 20:1.

In another aspect, the invention is directed to a crystalline composition comprising *S*-(-)-amlodipine D-hemitartrate DMAC monosolvate or, alternatively, *R*-(+)-amlodipine L-hemitartrate DMAC monosolvate, wherein at least 80% of the amlodipine in the crystalline composition is the predominant enantiomer. Preferably at least 90% of the amlodipine in the crystalline composition is the predominant enantiomer. More preferably at least 97% of the amlodipine in the crystalline composition is the predominant enantiomer. Most preferably at least 99% of the amlodipine in the crystalline composition is the predominant enantiomer.

In yet another embodiment, the invention is directed to solid pharmaceutical dosage forms comprising an optically active amlodipine or a pharmaceutically acceptable salt or hydrate thereof, and a carrier matrix, and to methods for manufacturing such dosage forms. In certain preferred embodiments, at least 80% of the optically active amlodipine in the dosage form is *S*-(-)-amlodipine, preferably at least 90%, or even 95% or more.

Detailed Description of the Invention

The present invention is based on the discovery that the resolution of amlodipine by precipitation with D- or L-tartaric acid from N,N'-dimethylacetamide

(hereinafter dimethylacetamide or DMAC) is suitable for the large scale production of enantiomerically enriched amlodipine.

The present invention encompasses the further discovery that a volatile, hydrophobic, non-chlorinated solvent such as methyl *t*-butyl ether (MTBE), ethyl acetate, toluene, or isopropyl acetate is useful in the secondary processing of the amlodipine hemitartrate DMAC monosolvate.

The present resolution method provides a solid (*e.g.*, granular or powder) form of optically active amlodipine.

I. Process for Optically Enriching Racemic Amlodipine

In general, the subject method includes forming a precipitate of amlodipine hemitartrate dimethylacetamide monosolvate from a solution comprising amlodipine and either D- or L-tartaric acid, whereby the amlodipine hemitartrate dimethylacetamide monosolvate precipitate is enriched for one enantiomer of amlodipine. The enantiomer of amlodipine, or a pharmaceutically acceptable salt or free acid thereof, along with a pharmaceutically acceptable carrier can then be formed into a solid tablet.

A. Precipitation of the amlodipine hemitartrate DMAC monosolvate

In one embodiment, the amlodipine hemitartrate DMAC monosolvate precipitate can be formed as follows. The absolute concentrations in this embodiment are merely exemplary, and can be varied as determined by routine experimentation. Racemic amlodipine free base is dissolved in a solvent comprising DMAC. The solvent comprises sufficient DMAC to induce crystallization of the DMAC solvate of amlodipine, *e.g.*, at least 50% DMAC, preferably at least 80%, at least 90%, approximately 100% DMAC, or otherwise consisting essentially of DMAC, and may include amlodipine solute at a concentration of about 0.55 M, for

example. If the starting material is an amlodipine acid addition salt, such as a besylate salt of amlodipine, the free base can be formed by any suitable technique as is well known in the art, such as extraction of an amlodipine salt suspension in MTBE (*e.g.*, about 0.25 M) with aqueous NaOH, followed by concentration of the resultant free base by vacuum distillation. To the free base solution in the solvent, is added D- or L-tartaric acid. The tartaric acid may be added as a solid or, preferably, as a solution in either DMAC, the solvent used to dissolve the amlodipine, or any other suitable solvent, optionally at a concentration of about 0.55 M. D-Tartaric acid is used to precipitate *S*-(-)-amlodipine as the *S*-(-)-amlodipine D-hemitartrate DMAC monosolvate and L-tartaric acid precipitates *R*-(+)-amlodipine as the *R*-(+)-amlodipine L-hemitartrate DMAC monosolvate. The ratio of tartaric acid to racemic amlodipine is preferably less than about 0.3 mol tartaric acid per mol racemic amlodipine or greater than about 0.7 mol tartaric acid per mol racemic amlodipine.

The mixture may be stirred, *e.g.*, for between 3 and 5 hours at room temperature or a temperature up to 80 °C, *e.g.*, between 60 and 80 °C, preferably 70 °C, as the amlodipine salt crystallizes from the solution during cooling, and the resultant crystals may be filter-separated from the solution, preferably at room temperature. The crystals may be washed, *e.g.*, successively with DMAC and MTBE, dried *in vacuo*, weighed, and assayed for optical purity. The above process is amenable to large-scale (1 kilogram and greater) resolution of amlodipine.

When practicing the method of the invention, a yield of about 80% of theoretical may be achieved with 99.5% enantiomeric purity. Those skilled in the art will appreciate that resolutions in which the enantiomeric purity is as low as 80% can be useful; however, enantiomeric purities of 90% or 99% are desirable.

Excellent results in performing the above method can be obtained using a 1:1 molar ratio in DMAC. When the ratio of tartaric acid to amlodipine is either low, *e.g.*, 0.25 mol or less tartaric acid per mol amlodipine, or high, *e.g.*, 0.75 or more mol tartaric acid per mol amlodipine, the racemic amlodipine is resolved with good

to excellent optical specificity, *e.g.*, providing at least 90% enantiomeric excess. However, when the ratio of tartaric acid to amlodipine is between 0.25-0.75:1.0, the racemic mixture is typically less well resolved. For example, the use of a tartaric acid:amlodipine ratio of 0.5:1.0 resulted in less than 80% enantiomeric purity.

While not wishing to be bound by any theory, the above-described results could arise because the hemitartrates of both enantiomers are insoluble and thus precipitate, while the monotartrate of one enantiomer is highly soluble and the monotartrate of the other enantiomer does not form to any appreciable extent. Equilibration of the salt mixtures at temperatures greater than room temperature, *e.g.*, between 60 and 80 °C, preferably 70 °C, provides enhanced opportunity for dissolution, equilibration and eventual preferred crystallization of the desired salt form containing amlodipine with at least 90% enantiomeric excess.

B. Precipitation of enantiomeric amlodipine free base

Enantiomeric amlodipine free base can be obtained from the enriched amlodipine hemitartrate DMAC monosolvate by a process of suspension in a substantially water-immiscible solvent, washed with aqueous NaOH, and precipitation by addition of a highly non-polar solvent, such as a hydrocarbon solvent, preferably an aliphatic hydrocarbon solvent.

In one exemplary embodiment, the enriched amlodipine hemitartrate DMAC monosolvate is suspended in MTBE at a concentration of about 0.15 M, and is successively extracted with 0.2 volumes aqueous NaOH and 0.2 volumes of water. The solution is then concentrated about three-fold by vacuum distillation and the precipitation of the product completed by addition of an equal volume of n-heptane. Other suitable solvents that can be used in place of or in addition to MTBE include ethyl acetate, toluene, xylene, isopropyl acetate, and the like, or any combination of two or more such solvents. Other suitable basic aqueous solutions, *e.g.*, having a pH above 8, preferably above 9, or even above 10, can be employed in place of the

NaOH solution, as will be understood by those skilled in the art. Other suitable solvents that can be used to facilitate precipitation of amlodipine free base include *n*-hexane and *n*-octane, as well as solvent mixtures such as ligroin, petroleum ether, and the like.

In certain embodiments, the above procedure provides a yield of about 85% of theoretical with an enantiomeric purity of the amlodipine of greater than 99.9%.

This procedure can also be employed for generating the free base from salts of amlodipine other than amlodipine hemitartrate DMAC monosolvate, such as amlodipine besylate, as will be understood by those skilled in the art. In certain such embodiments, the amlodipine salt is an acid addition salt of amlodipine and a chiral acid enriched to at least 90% enantiomeric excess.

C. Solid Dosage Forms

Formulations of optically active amlodipine suitable for oral administration may be in the form of capsules, cachets, pills, tablets, and the like, each containing a predetermined amount of amlodipine as an active ingredient.

In solid dosage forms for oral administration (capsules, tablets, pills, and the like), the optically active amlodipine is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate,

solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as capsules, pills, and the like, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the amlodipine therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the amlodipine only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The amlodipine can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

Additional information relating to solid dosage forms of amlodipine can be found in U.S. Patent Nos. 4,879,303, 5,178,867, and 6,057,344.

Exemplification

The invention now being generally described, it will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.

Example 1: *S*-(-)-amlodipine D-hemitartrate DMAC monosolvate

Aqueous sodium hydroxide (1 N, 530 mL) was added to a stirred suspension of amlodipine besylate (200 g, 0.353 moles) in methyl *t*-butyl ether (1.3 L). The reaction mixture was stirred for 20-30 minutes after which the aqueous and organic layers were allowed to separate. After removing the aqueous layer, water (220 mL) was added to the organic layer and the mixture was stirred for 20 minutes. The aqueous layer was again removed and the organic layer was concentrated to approximately one-third of its original volume by vacuum distillation. The organic layer was collected and concentrated to approximately one-third of its original volume by distillation. The concentrate was then mixed with *N,N*-dimethylacetamide (DMAC, 650 ml) and further concentrated by vacuum distillation until the temperature of the concentrate rose by 10-15 °C. The concentrate was allowed to equilibrate to room temperature and pressure before it was added to a stirred solution of D-tartaric acid (55.12 g, 0.367 mol) in *N,N*-dimethylacetamide (650 mL). The resulting slurry was stirred for 3-5 hr followed by filtration. After the residual crystalline solid was washed successively with dimethylacetamide (650 mL) and methyl *t*-butyl ether (650 mL), it was dried *in vacuo* at 40-50 °C for 8-16 hr to yield,

S-(-)-amlodipine D-hemitartrate DMAC monosolvate (85.5 g, 41% yield, 98.98% enantiomeric purity, >99% chemical purity).

Example 2: *S*-(-)-amlodipine free base

Aqueous sodium hydroxide (1 N, 220 mL) was added to a stirred suspension of *S*-(-)-amlodipine D-hemitartrate DMAC monosolvate (81.1 g, 0.142 moles) in methyl *t*-butyl ether (960 mL). The reaction mixture was stirred for 20-30 minutes after which the aqueous and organic layers were allowed to separate. After removing the aqueous layer, water (220 mL) was added to the organic layer and the mixture was stirred for 20 minutes. The aqueous layer was again removed and the organic layer was concentrated to approximately one-third of its original volume by vacuum distillation. After allowing the concentrate to equilibrate to room temperature and pressure, heptane (320 mL) was added and the resulting slurry was stirred for 1-2 hr. The slurry was then filtered, and the residual crystalline solid was washed with heptane (500 mL). The crystals were dried *in vacuo* at 40-50 °C for 8-16 h to yield *S*-(-)-amlodipine free base (49.10 g, 85% yield, 99.96% enantiomeric purity, >99% chemical purity).

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

All references, publications and patents cited in the specification above are herein incorporated by reference.

8. The method of claim 7, wherein converting the precipitate to amlodipine free base is accomplished by:
 - a. suspending the precipitate in an organic solvent consisting essentially of methyl *tert*-butyl ether, ethyl acetate, toluene, isopropyl acetate, or any combination thereof;
 - b. contacting the suspension with a basic aqueous solution to extract the tartrate ions into the aqueous solution; and
 - c. precipitating amlodipine free base from the organic solvent by reduction of the volume of organic solvent and addition of a non-polar organic solvent.
9. The method of claim 8, wherein the non-polar organic solvent comprises an aliphatic hydrocarbon solvent.
10. The method of claim 9, wherein the aliphatic hydrocarbon solvent is selected from n-hexane, n-heptane, and n-octane.
11. A composition comprising crystalline *S*-(-)-amlodipine D-hemitartrate dimethylacetamide monosolvate, wherein at least 80% of the amlodipine in the composition is *S*-(-)-amlodipine.
12. The composition of claim 11, wherein at least 90% of the amlodipine in the composition is *S*-(-)-amlodipine.
13. The composition of claim 11, wherein at least 97% of the amlodipine in the composition is *S*-(-)-amlodipine.
14. A composition comprising crystalline *R*-(+)-amlodipine L-hemitartrate dimethylacetamide monosolvate, wherein at least 80% of the amlodipine in the composition is *R*-(+)-amlodipine.

15. The composition of claim 14, wherein at least 90% of the amlodipine in the composition is *R*-(+)-amlodipine.
16. The composition of claim 14, wherein at least 97% of the amlodipine in the composition is *R*-(+)-amlodipine.
17. A composition consisting essentially of a solvate of an addition salt of amlodipine with a chiral acid enriched to at least 90% of one enantiomer of the chiral acid, wherein the composition is a free-flowing solid.
18. The composition of claim 17, wherein the addition salt is amlodipine hemitartrate.
19. The composition of claim 17, wherein the solvate is a dimethylacetamide solvate.
20. The composition of claim 17, wherein the solvate of an addition salt of amlodipine is amlodipine hemitartrate dimethylacetamide monosolvate.
21. The composition of claim 17, wherein the free-flowing solid is a powder or granular solid.
22. The composition of claim 17, wherein at least 80% of the amlodipine in the composition is *S*-(+)-amlodipine.
23. A solid medicament tablet comprising crystalline amlodipine or a granular salt or hydrate thereof, and one or more pharmaceutically acceptable carriers, wherein at least 80% of the amlodipine in the composition is *S*-(+)-amlodipine.

- 24 A method for purifying amlodipine free base from an addition salt of amlodipine with a chiral acid enriched to at least 90% of one enantiomer of the chiral acid, comprising:
- a. suspending the addition salt in a liquid consisting essentially of one or more non-chlorinated, substantially water-immiscible organic solvents;
 - b. contacting the liquid with a basic aqueous solution to extract the tartrate ions into the aqueous solution; and
 - c. precipitating amlodipine free base from the organic solvent by at least partial removal of the liquid and addition of a non-polar organic solvent.
25. The method of claim 24, wherein the one or more non-chlorinated, substantially water-immiscible organic solvents are selected from methyl *tert*-butyl ether, ethyl acetate, isopropyl acetate, or any combination thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 02/33894

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D211/90		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 25722 A (PFIZER LTD ;PFIZER RES & DEV (IE); PFIZER (US); SPARGO PETER LIONE) 28 September 1995 (1995-09-28) cited in the application example 1	17,18, 21,22
A	claims 1,5; examples 7,8	1-16,19, 20,23-25
P,X	EP 1 181 932 A (PFIZER LTD ;PFIZER (US)) 27 February 2002 (2002-02-27) example 1 --- -/-	17,18,21
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the international search 17 December 2002		Date of mailing of the international search report 30/12/2002
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Von Daacke, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/33894

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	EP 1 258 477 A (ZHANG XITIAN) 20 November 2002 (2002-11-20) example 1	17,18, 21,22
P,A	the whole document & WO 01 060799 A 23 August 2001 (2001-08-23) ----	1-16,19, 20,23-25
X	US 6 057 344 A (YOUNG JAMES W) 2 May 2000 (2000-05-02) cited in the application column 8, line 22-26; claims 1,2,7 ----	23
A	EP 0 295 333 A (RIFAR SRL) 21 December 1988 (1988-12-21) the whole document ----	1-25
A	EP 0 287 828 A (BYK GULDEN LOMBERG CHEM FAB) 26 October 1988 (1988-10-26) the whole document -----	1-25

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/33894

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9525722	A	28-09-1995	AT 166050 T	15-05-1998
			AU 677765 B2	01-05-1997
			AU 1949395 A	09-10-1995
			BR 9507137 A	30-09-1997
			CA 2186263 A1	28-09-1995
			CN 1144523 A , B	05-03-1997
			CZ 9602784 A3	12-03-1997
			DE 69502486 D1	18-06-1998
			DE 69502486 T2	10-09-1998
			DK 751938 T3	07-10-1998
			WO 9525722 A1	28-09-1995
			EP 0751938 A1	08-01-1997
			ES 2116737 T3	16-07-1998
			FI 963775 A	23-09-1996
			HU 76290 A2	28-07-1997
			IL 113008 A	14-07-1999
			JP 2843681 B2	06-01-1999
			JP 9510707 T	28-10-1997
			KR 188980 B1	01-06-1999
			NO 963991 A	19-11-1996
			NZ 282404 A	24-11-1997
			PL 316535 A1	20-01-1997
			RU 2132845 C1	10-07-1999
			TW 448156 B	01-08-2001
			US 6046338 A	04-04-2000
			US 5750707 A	12-05-1998
			ZA 9502362 A	23-09-1996
EP 1181932	A	27-02-2002	BR 0103434 A	26-03-2002
			EP 1181932 A2	27-02-2002
			JP 2002114683 A	16-04-2002
			US 2002045648 A1	18-04-2002
EP 1258477	A	20-11-2002	CN 1267669 A	27-09-2000
			AU 1849401 A	27-08-2001
			EP 1258477 A1	20-11-2002
			WO 0160799 A1	23-08-2001
US 6057344	A	02-05-2000	US 6291490 B1	18-09-2001
			US 2001029260 A1	11-10-2001
			US 2002010200 A1	24-01-2002
			AU 2221597 A	31-07-1997
			AU 3147593 A	28-06-1993
			CA 2124445 A1	10-06-1993
			EP 1262182 A2	04-12-2002
			EP 0661970 A1	12-07-1995
			EP 1013275 A2	28-06-2000
			JP 7501547 T	16-02-1995
			WO 9310779 A1	10-06-1993
EP 0295333	A	21-12-1988	US 5329001 A	12-07-1994
			AT 78257 T	15-08-1992
			AU 595410 B2	29-03-1990
			AU 8304187 A	22-12-1988
			CA 1339213 A1	05-08-1997
			CN 88100566 A , B	28-12-1988
			DE 3780454 D1	20-08-1992
			DE 3780454 T2	17-12-1992

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/33894

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0295333	A	DK 680487 A	18-12-1988
		EP 0295333 A2	21-12-1988
		ES 2051724 T3	01-07-1994
		FI 881039 A ,B,	18-12-1988
		GR 3005733 T3	07-06-1993
		HK 32793 A	08-04-1993
		JP 63316785 A	26-12-1988
		KR 9511744 B1	09-10-1995
		NO 880027 A ,B,	19-12-1988
		PH 24594 A	17-08-1990
		PT 86525 A ,B	31-05-1989
		SU 1595340 A3	23-09-1990
		YU 242887 A1	31-12-1988
		ZA 8709700 A	23-06-1988
EP 0287828	A	AU 1570588 A	02-11-1988
	26-10-1988	DE 3809912 A1	27-10-1988
		WO 8807524 A1	06-10-1988
		EP 0287828 A1	26-10-1988
		EP 0353238 A1	07-02-1990